Keywords: ipsen, drugs, show, early, promise, diabetes, clinical
Ipsen drugs show early promise in diabetes
Article | 28 April 1999
In early clinical studies, two somatostatin analogs developed byBeaufour Ipsen, BIM-23190 and BIM-23197, have been shown to suppress the release ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
